NCT06438757View on ClinicalTrials.gov

Trial of JYB1904 in Patients With Allergic Asthma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Allergic Asthma
Interventions
DRUG

JYB1904

Participants will receive JYB1904 every 8 weeks for 24 weeks.

DRUG

Omalizumab

Participants will receive Omalizumab every 2/4 weeks for 24 weeks.

Trial Locations (1)

201203

Shanghai General Hospital, Shanghai

Sponsors

Lead Sponsor

Jemincare
All Listed Sponsors
lead

Jemincare

INDUSTRY

NCT06438757 - Trial of JYB1904 in Patients With Allergic Asthma | Biotech Hunter | Biotech Hunter